RE001 T cell therapy for KRAS G12V solid tumors
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called RE001 for people with advanced solid tumors that have a specific genetic change (KRAS G12V mutation). It uses your own immune cells modified to target cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has not responded to standard treatments or cannot tolerate them.
- Your tumor must have the KRAS G12V mutation, and you must have a specific immune type called HLA-A*11:01.
- You need to be between 18 and 75 years old.
- You should be well enough to take care of yourself (ECOG score 0-1) and expected to live more than 6 months.
- Your heart, blood counts, and organ function must be within healthy limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
This Phase 1 trial tests an engineered immune cell treatment (“T cells”) made to recognize a specific tumor change (KRAS G12V) in people with advanced solid tumors. It’s intended for cancers that did not respond to standard treatments, and the goal is to see safety and early signs of benefit.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
Hear when a new KRAS G12V trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.